Bedrijfsoverzicht
Aldeyra Therapeutics, Inc. is a biotechnology entity dedicated to the discovery and development of novel therapies aimed at treating immune-mediated diseases. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which is characterized by high research and development costs and significant regulatory hurdles before products reach market. Its current market capitalization stands at $107.13M, while its annual revenue is not available for disclosure, and the organization employs 8 individuals. These financial metrics and operational scale indicate that Aldeyra Therapeutics is a micro-cap company with limited resources, relying heavily on the successful progression of its lead product candidate, reproxalap, to generate future economic value. The absence of reported revenue and the small employee count suggest the company is still in an early development phase, likely concentrating its capital on advancing clinical trials rather than commercial operations. This positioning within the biotechnology landscape implies a business model where value is derived from intellectual property and clinical data rather than current sales streams.
Financiële gezondheid
The company reports a net income of $-33,846,660 over the trailing twelve months, with an EBITDA of $-35,013,212, while revenue figures are not disclosed. The substantial gap between the reported net income and the EBITDA, alongside the lack of revenue data, reveals a cost structure dominated by research and development expenditures and clinical trial expenses rather than operational overhead associated with a mature commercial business. Free cash flow for the period was $-21,461,964, indicating that the company is burning cash to fund its growth initiatives, which limits its immediate financial flexibility but is typical for pre-revenue biotechnology firms. All three margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, which is consistent with a company that has not yet achieved commercial revenue or has incurred costs that exceed its current operational output. The company holds $70.04M in cash against $15.53M in debt, resulting in a debt-to-equity ratio of 35.10, suggesting a highly leveraged balance sheet relative to its equity base, though the absolute debt load is manageable given the cash reserves. The current ratio stands at 2.58, which indicates that the company maintains a conservative stance regarding short-term liquidity, possessing sufficient current assets to cover its current liabilities more than twice over. Return on Equity is -58.7% and Return on Assets is -25.0%, metrics that reveal management is currently utilizing shareholder capital to generate losses rather than profits, reflecting the inherent risk and capital intensity of the early-stage biotechnology sector.
Waarderingsbeoordeling
The trailing P/E ratio is not available due to the lack of earnings, whereas the forward P/E is listed as -6.91, a negative figure that implies the market is pricing in significant future losses or that earnings are expected to remain negative in the near term. The price-to-book ratio is 2.42, indicating that the market values the company's equity at a significant premium over its net asset book value, likely driven by the potential value of its intellectual property and pipeline assets rather than tangible book value. Since revenue is not available, the price-to-sales ratio is also not available, and the EV/EBITDA stands at -1.50, suggesting that traditional valuation multiples are distorted by the company's current negative earnings and high burn rate. The stock has a 52-week high of $6.17 and a 52-week low of $1.07, providing a wide range of volatility for investors to analyze. Without a specific current share price provided in the source data to calculate the exact percentage, the trading range demonstrates significant price discovery, with the stock capable of moving from the low end of $1.07 to the high end of $6.17 based on market sentiment regarding its clinical progress. The beta value is 1.33, which means the stock exhibits higher price volatility relative to the broader market, tending to amplify market movements with greater intensity than a standard market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, as the company has not yet generated commercial revenue to calculate these growth rates. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue, as the denominator for these calculations is currently zero or undefined in the context of public financial reporting. As a non-dividend payer, the company does not distribute any cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings and cash reserves are retained within the company to fund ongoing research and development activities. The overall growth and income profile is characterized by an absence of current income generation and traditional growth metrics, placing the company's value entirely on the potential future success of its drug candidates rather than historical financial performance or shareholder distributions.